TP53BP1 and cancer: As a result, treatment with ICRF-193 could have an even greater effect on cancer cells which have lost key molecules of the NHEJ pathway, such as 53BP1 or DNAPK, or other important DNA repair factors presented in this study, such as SLX4, and the Ercc1-XPF complex.